Premium
Front Cover: Design, Synthesis, and Biological Evaluation of Polyaminocarboxylate Ligand‐Based Theranostic Conjugates for Antibody‐Targeted Cancer Therapy and Near‐Infrared Optical Imaging (ChemMedChem 24/2018)
Author(s) -
Ren Siyuan,
Sun Xiang,
Wang Haixing,
Nguyen Trung Hai,
Sadeghipour Negar,
Xu Xiaochun,
Kang Chi Soo,
Liu Yujie,
Xu Hua,
Wu Ningjie,
Chen Yanda,
Tichauer Kenneth,
Minh David D. L.,
Chong HyunSoon
Publication year - 2018
Publication title -
chemmedchem
Language(s) - English
Resource type - Reports
SCImago Journal Rank - 0.817
H-Index - 100
eISSN - 1860-7187
pISSN - 1860-7179
DOI - 10.1002/cmdc.201800767
Subject(s) - conjugate , cancer research , epidermal growth factor receptor , antibody , antibody drug conjugate , panitumumab , chemistry , photodynamic therapy , chelation , cancer , medicine , monoclonal antibody , immunology , cetuximab , mathematical analysis , mathematics , organic chemistry
The Front Cover shows an antitumor agent CAB‐NE3TA (green) and a fluorescent dye IR800 (cyan) conjugated to an antibody (panitumumab, PAN) bound to epidermal growth factor receptor (EGFR). Rapidly dividing cancers require more iron than normal cells and are sensitive to depletion of cellular iron. The therapeutic antibody–drug conjugate (CAB‐NE3TA‐PAN) built on the cytotoxic iron chelator CAB‐NE3TA was effective in tumor suppression in human‐skin‐cancer‐bearing mice. This work demonstrates the potential of the therapeutic and theranostic conjugates for antibody‐targeted iron chelation therapy and fluorescent optical imaging of cancers. Cover artwork by David D. L. Minh et al. More information can be found in the Full Paper by Hyun‐Soon Chong et al. on page 2606 in Issue 24, 2018 (DOI: 10.1002/cmdc.201800598).